Druck Icon

Eckert & Ziegler Q1/2018: Sales increase of 9%; earnings remain below average

Berlin, 8 May 2018. Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related applications in medicine, science and industry, increased its sales from continuing operations in the first quarter 2018 by 9 % year on year to € 35.7 million. Earnings per share decreased by € 0.15 to € 0.44. This is primarily the result of temporary weak earnings in the Isotope Products segment that can be traced back to phasing effects.

Nevertheless, the Isotope Products segment – which increased its sales by € 2.9 million or 14 % to € 24 million due to the sales of the Gamma-Service Group newly acquired at the end of May 2017 – experienced the largest growth spurt within the continuing operations. Sales in the Radiation Therapy segment rose as well by € 0.7 million or 12 % to € 6.8 million, driven by the sales of WOLF Medizintechnik GmbH acquired in January. The Radiopharma segment sales remained at the previous year’s level of € 6.6 million.

The strong euro had adverse effects on the sales growth in all segments due to the adverse effects on foreign currency sales. Thus, compared with the previous year, the Group lost € 2.5 million, so that the growth after adjustment for currency effects would have totaled € 5.5 million or 17 %. Organic, real sales growth – in other words, sales adjusted for currency effects and excluding the acquisitions and disposals made in 2017 – amounted to € 1.4 million.

As a result of the sale of the Cyclotron unit and the repayment of existing loans as scheduled, the Eckert & Ziegler Group has only minor loan liabilities. Net liquidity, in other words cash less bank liabilities, amounts to € 51.9 million.

For the fiscal year 2018, net profit is expected to be at around € 2.20 per share and sales at around € 155 million, assuming that the euro exchange rate does not exceed $ 1.15.

The complete financial statements can be viewed here.

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine.
Contributing to saving lives.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.de